FINWIRES · TerminalLIVE
FINWIRES

$ISRG

11 stories mentioning ISRG

Every FINWIRES story that references ISRG, newest first.

Insider Trading

Intuitive Surgical Insider Sold Shares Worth $2,365,594, According to a Recent SEC Filing

Iman Jeddi, Senior Vice President and General Manager, da Vinci Platforms & Product Operations, on June 01, 2026, sold 5,625 shares in Intuitive Surgical (ISRG) for $2,365,594. Following the Form 4 filing with the SEC, Jeddi has control over a total of 33,112 common shares of the company, with 6,463 shares held directly and 26,649 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1035267/000210689826000015/xslF345X05/edgardoc.xmlPrice: $400.01, Change: $-12.25, Percent Change: -2.97%

$ISRG
Insider Trading

Intuitive Surgical Insider Sold Shares Worth $291,887, According to a Recent SEC Filing

Amy L Ladd, Director, on April 28, 2026, sold 619 shares in Intuitive Surgical (ISRG) for $291,887. Following the Form 4 filing with the SEC, Ladd has control over a total of 120 common shares of the company, with 120 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1035267/000178175026000002/xslF345X05/edgardoc.xml

$ISRG
Sectors

Sector Update: Health Care Stocks Mixed Late Afternoon

Health care stocks were mixed late Wednesday afternoon, with the NYSE Health Care Index down 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.1%.The iShares Biotechnology ETF (IBB) eased 0.1%.In corporate news, Biogen (BIIB) shares rose 2.2% after UBS upgraded the biotechnology company's stock to buy from neutral and boosted its price target to $225 per share from $185.Boston Scientific (BSX) shares jumped 8.3% after the company reported Q1 results exceeded Wall Street's estimates.Intuitive Surgical (ISRG) shares climbed 7% after the company lifted the full-year procedure growth outlook of its Da Vinci robotic surgery system and reported better-than-expected Q1 results.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that may be valued at more than $8 billion, Reuters reported. Merck shares rose 0.4%, and Inhibrx surged 35%.

$BIIB$BSX$INBX$ISRG$MRK
Sectors

Sector Update: Health Care Stocks Edge Higher in Afternoon Trading

Health care stocks edged up Wednesday afternoon with the NYSE Health Care Index little changed, paring earlier gains, and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.2%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, Boston Scientific (BSX) shares jumped 9.1% after the company reported Q1 results exceeded Wall Street's estimates.Intuitive Surgical (ISRG) shares climbed 7.7% after the company lifted the full-year procedure growth outlook of its Da Vinci robotic surgery system and reported better-than-expected Q1 results.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that may be valued at more than $8 billion, Reuters reported. Merck shares rose 0.2%, and Inhibrx surged 42%.

$BSX$INBX$ISRG$MRK
Wire

HSBC Adjusts Price Target on Intuitive Surgical to $604 From $653, Maintains Buy Rating

Intuitive Surgical (ISRG) has an average rating of overweight and mean price target of $584.08, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $486.73, Change: $+35.44, Percent Change: +7.85%

$ISRG
Wire

Barclays Cuts Price Target on Intuitive Surgical to $651 From $712, Maintains Overweight Rating

Intuitive Surgical (ISRG) has an average rating of overweight and mean price target of $584.08, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $485.44, Change: $+34.15, Percent Change: +7.57%

$ISRG
US Markets

Stocks Rise Pre-Bell as Trump Extends Iran Ceasefire; Tesla Earnings On Deck

The main US stock measures were trending higher in Wednesday's premarket activity after President Donald Trump extended the two-week US ceasefire with Iran, while traders await the latest round of corporate earnings, including results from Tesla (TSLA).The S&P 500 rose 0.6%, the Dow Jones Industrial Average increased 0.5% and the Nasdaq added 0.7% before the opening bell. The indexes finished Tuesday trading lower for the second consecutive session.In a social media post on Tuesday, Trump announced the extension of the two-week US ceasefire deal with Iran, citing a request by Pakistan's Prime Minister Shehbaz Sharif and Field Marshal Asim Munir. The truce was announced on April 7. The naval blockade of Iranian ports will continue, according to Trump."We have been asked to hold our attack on the country of Iran until such time as their leaders and representatives can come up with a unified proposal," Trump said in the post. "I have therefore directed our military to continue the blockade and, in all other respects, remain ready and able, and will therefore extend the ceasefire until such time as their proposal is submitted, and discussions are concluded, one way or the other."Iranian state news outlet Tasnim reported that negotiators from Tehran won't participate in further peace talks with their US counterparts, according to CNBC. US Vice President JD Vance's expected trip to Islamabad for peace talks with Iran has been called off, CNN reported, citing a White House official.West Texas Intermediate crude oil inclined 1.3% to $90.83 a barrel in premarket action, while Brent rose 1.1% to $99.56.The Trump administration is evaluating a potential extension of a maritime shipping waiver to make it easier to move oil and gasoline between US ports, Bloomberg News reported Wednesday, citing people familiar with the matter.Electric vehicle giant Tesla is scheduled to release its latest quarterly results after the markets close, along with International Business Machines (IBM) and Texas Instruments (TXN). GE Vernova (GEV), Philip Morris International (PM), AT&T (T), Boeing (BA), Boston Scientific (BSX) and Elevance Health (ELV) post earnings before the bell, among others.Intuitive Surgical (ISRG) shares advanced 2% pre-bell as the company lifted the full-year procedure growth outlook of its da Vinci robotic surgery system and reported better-than-expected first-quarter results. Advanced Micro Devices (AMD) gained 2%.Kevin Warsh said Tuesday that the Federal Reserve, under his leadership, would be independent from the White House, CNBC reported. Warsh, who is Trump's Fed chair nominee, made the remarks at his Senate Banking Committee confirmation hearing.Treasury yields were moving down before the open, with the two-year rate retreating 0.8 basis points to 3.77% and the 10-year rate off 1 basis point to 4.28%.Official data on Tuesday showed that retail sales last month logged the largest rise since March 2025 amid a surge in spending at gasoline stations as the Middle East conflict boosted energy prices.Wednesday's economic calendar has the weekly mortgage applications bulletin at 7 am ET, followed by the weekly EIA domestic petroleum inventories report at 10:30 am.Gold rose 1.1% to $4,769 per troy ounce, while bitcoin climbed 3.9% to $78,172.

Dow JonesNasdaq CompositeS&P 500$AMD$BA$BSX$ELV$GEV$IBM$ISRG$PM$T$TSLA$TXN
US Markets

Intuitive Surgical Raises 2026 Procedure Growth Outlook Following First-Quarter Beat

Intuitive Surgical (ISRG) shares rose early Wednesday as the company lifted the full-year procedure growth outlook of its da Vinci robotic surgery system and reported better-than-expected first-quarter results.The robotic surgical systems firm now anticipates worldwide da Vinci procedure growth of between 13.5% and 15.5% for 2026, compared with its previous projections for a gain of 13% to 15%, Dan Connally, head of investor relations, said during a late Tuesday earnings call, according to a FactSet transcript. The stock rose 2% in the most recent premarket activity."We continue to expect primary growth drivers in 2026 to be generally consistent with those in 2025, including general surgery in the US and procedures outside of urology internationally," Connally said on the call.Adjusted gross profit margin is now pegged to be in a range of 67.5% to 68.5% of revenue, compared with the prior forecast of 67% and 68%. The latest guidance includes a tariff-related headwind of 1% of revenue, according to the company."We think there should be system (revenue) and procedure upside potential relative to our estimates (and guidance) which should translate to meaningful EPS beats," Truist Securities said in a client note. The brokerage has a buy rating on Intuitive Surgical's stock.The firm posted adjusted earnings of $2.50 a share for the March quarter, up from $1.81 the year before, ahead of the FactSet-polled consensus of $2.12. Revenue rose 23% to $2.77 billion, topping the Street's view of $2.62 billion."We are pleased with company performance this quarter, which was marked by expanded adoption of our da Vinci, Ion and digital platforms," Chief Executive Dave Rosa said in the earnings statement.Revenue in the instruments and accessories segment advanced 23% to $1.69 billion. The increase was mainly driven by a roughly 16% jump in the number of da Vinci procedures, customer buying patterns and a 39% surge in Ion procedure volume, according to the company. Procedures in the US inclined 15% and gained 20% outside the country, Chief Financial Officer Jamie Samath said on the call.Systems revenue amounted to $650.7 million, up from $522.7 million a year ago. The firm placed 431 da Vinci surgical systems during the quarter, up from 367 last year. Services revenue increased to $433.7 million from $363 million.

$ISRG
Research

Research Alert: CFRA Keeps Buy Rating On Shares Of Intuitive Surgical, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $590 from $645, 52.7x our 2027 EPS estimate, below ISRG's five-year average forward P/E of 58x. We raise our 2026 EPS forecast to $10.09 from $9.78 to reflect the Q1 beat and maintain our 2027 EPS estimate at $11.19. We maintain a neutral outlook on the health care equipment sub-industry, as we see positive long-term tailwinds balancing out near-term headwinds. We think that the sub-industry's underperformance relative to the S&P 500 since the beginning of the year accentuated since the onset of the U.S.-Iran conflict in February. This reflects investor caution around near-term operational challenges for Medtech companies, particularly around supply chain, despite the sub-industry's attractive longer-term growth trajectory. We think ISRG shares are trading attractively at current valuations given its robust outlook despite the weakness seen in recent months, which we mainly attribute to the overall negative sentiment for the sub-industry's near-term pressures.

$ISRG
Research

Research Alert: Intuitive Surgical Q1: Robust Growth In Revenue, Eps, And Procedures Volumes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Intuitive Surgical delivered robust Q1 2026 results with non-GAAP EPS of $2.50, beating the $2.11 consensus estimate (+38% Y/Y). Revenue surged to $2.77B (+23% Y/Y), above the $2.6B consensus view, driven by worldwide procedures growing 17% Y/Y with da Vinci procedures up 16% and Ion procedures accelerating 39%. System placements reached 431 da Vinci systems versus 367 in Q1 2025, while da Vinci 5 placements surged to 232 systems from 147, showing strong adoption of the next-generation platform. Management guided worldwide da Vinci procedure growth of 13.5%-15.5% with non-GAAP gross margins expected at 67.5%-68.5%, incorporating an estimated 1.0% revenue impact from current tariffs. The installed base reached 11,395 da Vinci systems (+12% Y/Y), while non-GAAP gross margin expanded to 67.8% from 66.4% and operating income grew 40% Y/Y, demonstrating strong operational leverage with a robust balance sheet of $7.98B in cash.

$ISRG
Wire

Mizuho Adjusts Price Target on Intuitive Surgical to $525 From $575, Maintains Neutral Rating

Intuitive Surgical (ISRG) has an average rating of overweight and mean price target of $602.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $453.27, Change: $+2.65, Percent Change: +0.59%

$ISRG
ISRG News | FINWIRES